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Myogenin is the dominant transcriptional regulator of embryonic and fetal muscle differentiation and during
maturation is profoundly down-regulated. We show that a highly conserved 17-bp DNA cis-acting sequence
element located upstream of the myogenin promoter (myogHCE) is essential for postnatal repression of
myogenin in transgenic animals. We present multiple lines of evidence supporting the idea that repression is
mediated by the Y-box protein MSY-3. Electroporation in vivo shows that myogHCE and MSY-3 are required
for postnatal repression. We further show that, in the C2C12 cell culture system, ectopic MSY-3 can repress
differentiation, while reduced MSY-3 promotes premature differentiation. MSY-3 binds myogHCE
simultaneously with the homeodomain protein Pbx in postnatal innervated muscle. We therefore propose a
model in which the myogHCE motif operates as a switch by specifying opposing functions; one that was
shown previously is regulated by MyoD and Pbx and it specifies a chromatin opening, gene-activating function
at the time myoblasts begin to differentiate; the other includes MYS-3 and Pbx, and it specifies a repression
function that operates during and after postnatal muscle maturation in vivo and in myoblasts before they
begin to differentiate.
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Muscle-specific transcription factors of the MyoD family
(MRFs) are members of a regulatory network that drives
skeletal muscle determination and differentiation during
embryonic and fetal development. Among the four
MRFs, myogenin is critical because it is the one required
for correct differentiation of virtually all embryonic and
fetal muscle. Germline ablation of myogenin blocks dif-
ferentiation and null mice die at birth from lack of
muscle fiber development and consequent muscle insuf-
ficiency (Hasty et al. 1993; Nabeshima et al. 1993). Myo-
genin is expressed prominently at the onset of myocyte
differentiation as embryonic and fetal development pro-
ceed, with recruitment of new myoblasts to the differ-
entiated state continuing throughout this period and
into the early postnatal period (Sassoon et al. 1989;
Wright et al. 1989; Hannon et al. 1992). In healthy wild-
type adult muscle, myogenin is down-regulated, as
muscle matures, around the time of innervation, but it
can be up-regulated later during muscle regeneration in
response to diverse stimuli (e.g., Grounds et al. 1992),
during aging (Musarò et al. 1995; Kostrominova et al.
2000), and upon denervation (Eftimie et al. 1991; Buo-
nanno et al. 1992). Knocking out myogenin perinatally
leads to a generally normal skeletal muscle phenotype,
but with reduced body size (Knapp et al. 2006).
At the molecular level, myogenin interacts with many
muscle-specific target genes, associated with muscle dif-
ferentiation, including nAChR subunits, by binding to
one or more E-boxes (5-CANNTG-3) present in their
promoters and transcriptional enhancers (Piette et al.
1990; Prody and Merlie 1991; Berberich et al. 1993;
Walke et al. 1996). During postnatal development the
major functional maturation event is motor innervation,
which activates a cascade of calcium-dependent signals,
leading to overall reduced myogenin and MyoD RNA
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levels. This is thought to be important for reducing ex-
pression in extrasynaptic regions of synaptic proteins
such as AChR subunits, which are positively regulated
throughout the fiber by MyoD and myogenin during
early muscle development but later become restricted to
synaptic regions during and after innervation (Sanes and
Lichtman 2001). When challenged by denervation, myo-
genin is up-regulated, and its target AChR RNAs and
proteins reappear in extrasynaptic regions along the
muscle fiber.
How neural activity controls myogenin in postnatal
muscle has been the subject of several studies that sug-
gest contributions from multiple mechanisms. A post-
translational pathway has been reported in which extra-
cellular calcium enters through voltage-activated chan-
nels and increases activities of PKC and CaMKII, leading
to phosphorylation of myogenin protein. This post-trans-
lational modification inhibits myogenin binding to E-
boxes on nAChR promoters, resulting in reduced nAChR
expression (Mendelzon et al. 1994; Macpherson et al.
2002). Subsequently, it was proposed that an additional
but otherwise unspecified transcriptional mechanism
also inhibits myogenin expression in response to inner-
vation (Blagden et al. 2004). The post-translational
mechanism could act on a rapid time scale and, among
other activities, it could disrupt the positive autoregula-
tory feedback of myogenin on its own enhancer. Recent
studies have further probed transcriptional repression of
myogenic target genes that involves recruiting HDAC
complexes. So far, two well-known sequence-specific
DNA-binding transcription factors, MEF2 and Six-1,
have been shown to interact with different histone
deacetylases HDACs (Mejat et al. 2005; Tang and Gold-
man 2006; Cohen et al. 2007), and there are conserved
sites for both of these regulators in the 1-kb proximal
enhancer/promoter region of myogenin that has been
studied in some detail (Edmondson et al. 1992; Cheng et
al. 1993; Yee and Rigby 1993; Spitz et al. 1998). The Mef2
and Six transcription factor/corepressor/HDAC sets ap-
pear to contribute some partial repression of myogenin,
and each can apparently be converted to a positive regu-
latory complex by replacing corepressors/HDAC activity
with coactivators.
Additional regulatory sequences in the myogenin gene
have been identified between −1102 and −1565, and
these respond to experimental denervation in the adult
(Buonanno et al. 1993; Gibney and Buonanno 1995).
In this work, we show that a third DNA motif, which
is located within the 1.1-kb myogenin proximal regula-
tory region and positioned upstream of the MRFs, MEF2,
and Six sites, mediates profound postnatal down-regula-
tion of myogenin RNA. We were initially motivated to
study this element by results of comparative genome
sequence analysis, which showed it to be highly con-
served (myogHCE). This sequence region was indepen-
dently shown to bind the homeodomain protein Pbx, in
close collaboration with MyoD. It contributes to positive
regulation of myogenin at the onset of its expression in
differentiating (Berkes et al. 2004). We now find that this
motif has an alternative and strong repressing regulatory
action in postnatal muscle maturation that is associated
with binding of MSY-3 in vitro and in vivo.
MSY-3 was not previously known to be part of the core
muscle gene regulatory network. It is a member of the
cold-shock domain (CSD) family of proteins (also known
as Y-box proteins). CSD proteins are characterized by a
common DNA/RNA-binding region called the “cold-
shock domain,” which is conserved from bacteria to
mammals (Graumann and Marahiel 1998; Matsumoto
and Wolffe 1998). Experiments reported here suggest that
MSY-3 mediates the normal postnatal down-regulation
of myogenin that is associated with innervation. We also
find that, in the C2C12 cell culture system, elevated
MSY-3 levels can repress expression of differentiation of
specific genes, while reduced MSY-3 can promote pre-
mature differentiation. We therefore consider implica-
tions of a compound DNA motif capable of binding two
different complexes—one including MyoD and Pbx and
executing a chromatin opening, gene-activating func-
tion, and another at a later time in normal development,
that includes MSY-3 and executes a repression function.
We discuss the implications for sequence conservation
of any situation in which multiple factor recognition
supports different functions, such as the switch from an
early myogenin-on state in developing myocytes to a
later myogenin-off state in mature innervated muscle
fibers.
Results
Multispecies comparative genome analysis highlights
a myogenin promoter conserved element
An especially conserved sequence feature (myogHCE)
was highlighted using MUSSA, a software tool that au-
tomatically integrates multigenome genome compari-
sons and allows for interactive visualization (http://mussa.
caltech.edu). This highly conserved element is defined
by a core motif of 17 bp shared perfectly across five mam-
malian genomes (Supplemental Fig. 1A) and surprisingly
was also found identical to mammals in pufferfish ge-
nomes (Supplemental Fig. 1B). The sequence is located
between −101 and −117 bp upstream of the myogenin
transcription start in mouse (chr1: 136,106,084–
136,106,132) and falls within the 1.0-kb proximal pro-
moter/enhancer that is sufficient to recapitulate the ma-
jor features of myogenin expression during embryonic
and fetal development (Yee and Rigby 1993).
We next asked if there are other sequences in the ge-
nome that are very similar to the myogHCE and also
conserved in multiple mammalian genomes. To do this
we first retrieved the corresponding sequence from addi-
tional vertebrates (Supplemental Fig. 1B). This intro-
duced evolutionary variation, which enabled us to build
a position-specified frequency matrix (PSFM) model for
myogHCE (Supplemental Material; Mortazavi et al.
2006). The purpose of a PSFM model is to capture al-
lowed variation in a motif. This makes possible compu-
tational searches for similar sequences that are scored
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and ranked in a way that is sensitive to the probability of
a given nucleotide at each position.
The resulting PSFM model for the myogenin HCE was
used to search genome-wide for additional high scoring
sites that passed a threshold (0.9 match score) in each of
three mammalian genomes (human, mouse, and dog), as
described previously. We then identified the gene asso-
ciated with each of these instances by applying the cis-
Matcher algorithm (Mortazavi et al. 2006). There were
only 19 such highly conserved instances associated with
orthologous genes in the three genomes (Supplemental
Table 1). One of these was located ∼35 kb upstream of
mouse MyoD (−32 kb in human) where it is embedded in
a larger conserved, noncoding region that has not, to our
knowledge, been studied previously. The PSFM model
was converted to a conventional consensus sequence to
permit direct scanning of Transfac. No perfect matches
were found to known consensus sites in that database.
MyogHCE affects myogenin and AChRs extrasynaptic
expression during postnatal muscle maturation
We first tested for functional activity of the myogHCE
by constructing a set of lentiviral LacZ reporter genes
containing wild-type or mutant myogHCEs, in the con-
text of the 1.1-kb myogenin promoter that drives expres-
sion in embryo and fetal muscle (Cheng et al. 1993; Yee
and Rigby 1993; Venuti et al. 1995). In each of two inde-
pendent mutant reporter constructs, the myogHCE was
replaced by a different randomized sequence of base
composition similar to myogHCE (Supplemental Fig. 2).
Prior work had shown that a wild-type 1.1-kb myogenin
promoter, in a lentiviral vector, drives GFP expression in
a pattern that nicely recapitulates RNA in situ data at
day 11.5 of embryonic development (Lois et al. 2002).
Initial experiments compared each mutated version,
MYOmutL and MYOmutT, with the wild-type (MYOwt)
version in embryos. -gal staining of 10.5-, 11.5-, and
12.5-d-post-coitum embryos delivered strong myogenin
patterns from the wild-type construct in spatiotemporal
domains in which populations of myoblasts are continu-
ally and actively turning on myogenin in this period,
including newer somites of the axis and the limbuds.
The mutant construct’s staining patterns were not de-
tectably different from the wild-type construct (Supple-
mental Fig. 3; see the Discussion).
We then asked if mutation of the HCE affects expres-
sion in postnatal and adult muscle. Wild-type reporter
gene expression was prominent in the first weeks of
postnatal life, in agreement with previous studies using
conventional transgenesis, and it then declines (Buo-
nanno et al. 1993). Muscle cross-sections from 1- to
5-mo-old animals show progressively less LacZ staining.
This tracks the temporal pattern of endogenous myo-
genin and AChR expression in postnatal life. Further-
more, after >1 yr, some myonuclei again score positive,
but at low frequency. This agrees with previously re-
ported “re-expression” of myogenin in aged mice
(Musarò et al. 1995). In contrast, cross-sections and
muscle fibers from the mutant HCE reporter transgenics,
MYOmutL, showed strong persistence of expression
through the period of postnatal maturation (Fig. 1A;
Supplemental Fig. 4A). RNA levels were directly quan-
tified by qRT–PCR in MYOmutL and MYOmutT, con-
firming that the postnatal wild-type reporter reduction
occurs at the RNA level, that it mirrors diminution in
endogenous myogenin RNA (Fig. 1B; Supplemental Fig.
4B), and that an intact myogHCE is required for this
down-regulation (Supplemental Table 2). We used trans-
genic mouse lines derived by conventional methods to
confirm that expression of the HCE mutant reporter per-
sists in postnatal life. Moreover, no differences in mu-
tant reporter expression were seen upon experimental
denervation (Fig. 1C; Supplemental Fig. 4C).
We next established that, in a standard acute transfec-
tion assay in healthy adult muscle, a LacZ reporter
driven by HCE mutant myogenin promoters shows the
expected increase of LacZ positive myonuclei compared
with the corresponding wild-type HCE-driven construct
(Fig. 1D). Results were identical for the two different
mutant constructs. We could then ask whether expres-
sion of the myogenin-coding sequence, identically
driven by the mutant HCE-containing myogenin pro-
moter, could alter expression of known innervation-de-
pendent endogenous genes, as one would predict if HCE-
mediated regulation is critical for innervation-dependent
regulation. Myogenin and  AChR RNA and protein ex-
pression increased in muscle containing the HCE mu-
tant-driven myogenin, but not with the control wild-
type myogenin construct (Fig. 2A). Since it is known that
denervation causes elevated transcription of AChRs in
extrasynaptical region along the entire length of the
muscle fiber (Fontaine et al. 1988; Goldman and Staple
1989; Gundersen et al. 1995), we also verified that the
distribution of the AChR is high and diffuse, as would be
predicted, for several millimeters from synaptic junc-
tions when myogenin is driven from the HCE mutant
promoter compared with the wild-type promoter (Fig.
2B, bottom) and comparable with the distribution of
AChRs in extrasynaptic regions of denervated muscle
(Fig. 2B, top and graph). This finding suggests that the
HCE-dependent expression pathway for myogenin con-
tributes significantly to the biology of mature muscle by
helping to restrict spatiotemporal expression of AChRs
to the domain near mature neuromuscular junctions.
Msy3 binds myogHCE
To search for proteins that interact with myogHCE and
in muscle maturation, electrophoretic mobility shift as-
says (EMSA) were performed with nuclear extracts from
skeletal muscle of 3-mo-old mice. Five complexes were
seen of which only two (Fig. 3A, arrows) were substan-
tially competed by the unlabeled myogHCE DNA but
not by excess mutant HCE DNA. These complexes were
not detected in nuclear extracts from younger mice (1–2
wk), and they were no longer detectable after denerva-
tion. The MCK enhancer, a known regulatory region ac-
tive in differentiated skeletal muscle (Lassar et al. 1989),
served as a control for the active state of the extracts and
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for the EMSA assay. As expected, it produced a consis-
tent binding pattern from the extracts and at all ages,
confirming their activity and integrity (Fig. 3B).
To identify proteins that bind the myogHCE, we en-
riched the protein recognition complex by affinity chro-
matography from nuclear extracts of skeletal muscle iso-
lated from 3-mo-old mice. We verified that a fraction of
this preparation was enriched for the nuclear binding
activity of myogHCE by EMSA (Supplemental Fig. 5A).
An LC-MSMS mass spectrometry assay (MudPIT as per-
formed in Graumann et al. 2004) revealed that MSY-3, a
CSD protein (also known as CsdA, MY1, dpbA, YB-2,
ZONAB, or MSY-4), is a significant component identi-
fied with 33% coverage of seven unique peptides. As a
group, CSD proteins bind DNA and RNA and they par-
ticipate in both transcriptional activation and repression
in other systems; there is also some evidence that they
can affect post-transcriptional regulation (Coles et al.
2000; Kohno et al. 2003). Two forms of MSY-3 mRNA,
MSY-3S and MSY-3L, are produced by alternative splic-
ing. Their translated products either possess or lack a
69-amino-acid C-terminal domain. Both isoforms are
abundantly expressed in spermatogenic cells, but they
are generally at low levels in other adult tissues, except
that the MSY-3S isoform is present in heart and abun-
dant in skeletal muscle (Mastrangelo and Kleene 2000).
In Figure 6A (below) and Supplemental Figure 6, we
show expression of MSY-3 protein at different times dur-
ing development. The protein was detected in embryonic
liver, brain, kidney, heart, and skeletal muscle, while in
the adult it was only prominent in testis, heart, and skel-
etal muscle. Both MSY-3 isoforms are detected in adult
muscle fibers, with the MSY-3 short isoform always
much more abundant than the MSY-3 long isoform; their
expression ratio remains constant during development
(Supplemental Fig. 6B,C).
CSD proteins were first identified by their binding to
an inverted 5-CCAAT-3 repeat, but they are considered
to generally prefer a range of CT-rich sequences (Shan-
non et al. 1997). We confirmed the mass spec iden-
tification by immunoblotting with the ZONAB anti-
body (Penes et al. 2005) developed against the canine
ortholog of MSY-3 (Supplemental Fig. 5B). We next asked
whether MSY-3 has significant innervation-dependent
myogHCE-binding activity, as predicted from the way
we identified it. EMSA experiments show that this an-
tibody specifically immunocompeted the mobility shift
maturation-innervation dependent, whereas addition of
Figure 1. MyogHCE mediates myogenin
RNA levels during postnatal muscle
maturation. (A) -gal-stained leg mus-
cle of transgenic mice carrying reporter
driven by wild-type myogenin pro-
moter (MYOwt) or mutant at myogHCE
(MYOmutL). Mouse ages were postnatal 1
wk (1w), 1 or 5 mo (1M, 5MM), or 1 yr (1Y).
Bar, 400 µm. (B) Measurements of the ex-
pression level of the transgene LacZ by
qRT–PCR in leg muscle of transgenic mice
carrying the wild-type myogenin pro-
moter (MYOwt) or mutant at myogHCE
(MYOmutL, MYOmutT). Mouse ages
were postnatal 1 wk (1w) and 1, 2, or 5 mo
(1M, 2MM, 5MM). The expression level is
normalized by the endogenous myogenin.
Each point derives from RNA isolated
from three independent transgenic mice.
(C) Measurements of the expression level
of the transgene LacZ by qRT–PCR in con-
trol or denervated (D) leg muscles of trans-
genic mice carrying the wild-type myo-
genin promoter (MYOwt) or mutant at
myogHCE (MYOmutL). Mouse ages were
postnatal 1 wk (1w) and 2 mo (2MM). The
expression level is normalized by the en-
dogenous myogenin. Expression levels of
LacZ are reported in Supplemental Figure
4. Each point derives from RNA isolated
from three independent transgenic lines.
(D) -gal-stained leg muscle of 2-mo-old
mice, previously electroporated with con-
structs carrying reporter driven by wild-
type myogenin promoter (MYOwt) or mu-
tant at myogHCE (MYOmutL) and nuclear GFP. Bar, 400 µm. Panels at the left indicates the GFP positive and on the right the LacZ
positive nuclei. The graph shows the expression levels of electroporated LacZ transgene and nGFP measured by qRT–PCR.
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a control IgG had no effect, suggesting that the ZONAB
binding masks the DNA-binding site of the MSY-3-asso-
ciated protein complex (Fig. 3C).
Can MSY-3 bind myogHCE in the absence of other
muscle nuclear extract components? EMSA was per-
formed with a GST-MSY-3 fusion protein that was incu-
bated with myogHCE oligonucleotides in both double-
stranded and single-stranded forms. In this experiment,
MSY-3 retarded migration of single-stranded target
DNA, in agreement with previous studies that reported
that MSY-3 preferentially binds sense ssDNA (Coles et
al. 2005). We also observed retarded migration of double-
stranded target DNA, even though to a lesser extent
quantitatively in comparison with the single strand. In-
cubation with a mutant oligo, MYOmutL, lacking the
myogHCE, revealed that the myogHCE motif is respon-
sible for MSY-3 binding (Fig. 3D).
MSY-3 can inhibit differentiation and requires
myogHCE to repress myogenin
A simple hypothesis based on the lentiviral transgenic
results is that a repressor complex binds at the
myogHCE during skeletal muscle maturation, and the
proteomics screen suggests that MSY-3 is a candidate for
mediating all or part of the observed repression. We
therefore asked whether added MSY-3 expression could
repress myogenin in culture. Multiple, stably transfected
MSY-3 C2C12 cell lines were established and analyzed.
C2C12 myoblast clones overexpressing MSY-3 protein
were compared with control C2C12 transfected clones,
and myogenin was down-regulated at 24–48 h of differ-
entiation (Fig. 4A) relative to control lines. Their ability
to fuse into myotubes and synthesize MHC was also
markedly impaired (Fig. 4A, left panels). Effects of extra
MSY-3 were not limited to C2C12, as similar results
were obtained for MyoD-converted 10T1/2 cells, in
stable and transient transfection formats (Supplemental
Fig. 7). We conclude that myogenic differentiation can be
disrupted by elevating MSY-3. MSY-3 RNA is expressed
in proliferating C2C12 myoblasts and is normally
weakly down-regulated during differentiation in myo-
tubes (Supplemental Fig. 8), so we asked if reducing it
further by RNAi could affect differentiation. If MSY-3
normally represses myogenin in myoblasts, then suc-
cessful MSY-3 knockdown, under the simplest model,
could cause premature myogenin expression and/or in-
crease its rate of accumulation, with the net effect of
Figure 2. MyogHCE controls AChRs ex-
trasynaptic expression during postnatal
muscle maturation. (A) Measurements of
the myogenin and AChR  transcripts by
qRT-PCR and immunoblot in leg muscle
of 2-mo-old mice (control), after 48 h from
denervation (denervated), or electroporated
with constructs carrying myogenin cDNA
driven by 1.1-kb wild-type myogenin pro-
moter (MYOwtMYO) or mutant at
myogHCE (MYOmutLMYO), or an empty
pcDNA3 vector. Statistical significance of
AChR  transcripts measurements in mu-
tant MYOmutLMYO and in the denervat-
ed is P > 0.05. (B) The images show the
AChRs density visualized by autoradiogra-
phy of longitudinal sections from tibialis
anterior muscle innervated (control) or
48-h denervated muscle in synaptic and ex-
trasynaptic fiber segments (3 mm from the
synaptic junctions) (top) or in extrasynap-
tic fiber segments (3 mm from the synaptic
junctions) of tibialis anterior muscle elec-
troporated with an empty pcDNA3 vector,
myogenin cDNA driven by the wild-type
myogenin promoter (MYOwtMYO) or the
mutant at myogHCE (MYOmutLMYO) in-
cubated with 125I--bungarotoxin (bot-
tom). The sections were subsequently cov-
ered with a monolayer of photographic
emulsion and after exposure and develop-
ment silver grains were counted in
250-µm2 fields along the length of the sec-
tions, 3 mm on each side of the synapse
(graph). The areas of high grain density in
the left top panels correspond to the end-
plate region of the fibers. Bar, 400 µm.
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accelerating myogenin-regulated differentiation pheno-
types. When a pool of four siRNA oligos targeting both
MSY-3 isoforms was used in C2C12 cultures, strong ac-
tivation (10- to 14-fold) of myogenin and its target genes,
 AChR and MCK, was observed (Fig. 4B). A weaker
up-regulation (approximately threefold) of MyoD was
also observed. By immunostaining for myogenin protein
in cell cultures treated with MSY-3 or control siRNAs,
precocious positive cells were seen under proliferation-
promoting, myoblast conditions (growth medium [GM]),
where myogenin is normally absent (Fig. 4B, right pan-
els). Furthermore, we could rescue the differentiation ca-
pacity of a C2C12 MSY-3-overexpressing clone (clone 5)
by MSY-3 RNAi, whose effect was monitored as demon-
strated by measuring MHC (Supplemental Fig. 9). Dele-
tion of the CSD strongly abrogates the ability of an
MSY-3 expression construct to repress myogenin levels
or myogenesis and induced a hypertrophic phenotype,
which is absent in other mutants or in the control (Fig.
4C). Mutation of the MSY-3 protein in its putative DNA-
binding domains showed that deletion of the CSD also
prevented binding to both single-sense (SS) and double-
stranded (DS) myoHCE DNA (Supplemental Fig. 10).
These results suggest that DNA binding mediated
through the CSD is required for myogenic inhibition.
The gain-of-function and loss-of-function experiments
described above suggest that MSY-3 behaves as a repres-
sor of myogenesis. To further probe the mechanism, we
asked whether MSY-3 acts through the myogHCE motif
in C2C12 differentiation. To do this, we made multi-
clonal transformant pools carrying a stably transfected
nuclear LacZ reporter driven by the 1.1-kb wild-type
myogenin promoter or by either of its two myogHCE
mutated versions (MYOmutL and MYOmutT, the same
mutant versions used in the transgenic analysis); then
we transfected each reporter pool with a construct that
drives expression of MSY-3 (Msy) or with a mock vector
(pc). LacZ reporter RNA was quantified by qRT–PCR
throughout differentiation. In the absence of added MSY-
3, mutated and wild-type myogenin constructs increased
similarly (Fig. 5A). With excess MSY-3, a greater increase
was observed from mutant promoters (MsymutL or
MsymutT) versus wild type (MsywtM) in late differen-
tiation (96 h). This recapitulates the effect of MSY-3
overexpression on endogenous myogenin. These data
demonstrate the ability of MSY-3 to regulate expression
from the myogenin promoter but also show that the ef-
fect is context-dependent and becomes significant later
in differentiation when MyoD levels are diminished and
its binding is diminished relative to earlier times
(Supplemental Fig. 11). This suggests that mutual exclu-
sivity between MSY-3 and MyoD could mediate the
choice between an open and induced myogenin promoter
and a repressed one.
To determine if MSY-3 associates directly with the
myogenin locus in vivo we performed chromatin immu-
noprecipitation (ChIP) from proliferating and differenti-
ating C2C12 myoblasts, using the ZONAB antiserum
against the MSY-3 protein. Chromatin immunoprecipi-
tated from proliferating C2C12 myoblasts with ZONAB
Figure 3. Innervation-sensitive complexes require the
myogHCE element. MSY-3-binding specificity. (A) Pro-
tein-binding complexes formed in vitro (arrows), as-
sayed by EMSA, are detected on myogHCE oligo from
muscle nuclear extracts of 3-mo-old mice. Labeled
MYOwt oligo competed with 10–100–200× excess of
cold competitor wild type (MYOwt, lanes 2–4) or mu-
tated (MYOmutL, lanes 5–7), as indicated. Oligo se-
quences are shown in the box. (B) EMSA complexes
(arrows) at myogHCE from nuclear extracts 3-mo-old
mice (lane 1) are absent from nuclear extracts of 2 and 1
wk (lanes 2,3) and from nuclear extracts of 3-mo-old
mice denervated 24, 48, and 72 h before (lanes 4–6).
Control MCK promoter EMSA (lanes 7–12) shows spe-
cific complex from all samples. (C) EMSA of nuclear
extracts of muscle of 3-mo-old mice with myogHCE
32P-labeled oligonucleotide in the presence of ZONAB
antibody (lanes 2,3, 1–5 µg) or control IgG (lane 4, 5 µg).
Arrows indicate the specific, asterisks indicate the non-
specific, and arrowheads the immunocompeted mobil-
ity shift maturation-innervation dependent protein
complexes. (D) EMSA assay of GST and GST-MSY-3
fusion protein with myogHCE 32P-labeled oligonucleo-
tide in single strand forms (lanes 1,2 sense; lanes 4,5
antisense) and in a double strand (lanes 7, 8) and GST-
MSY-3 protein with mutant myogHCE 32P-labeled oli-
gonucleotides MYOmutL in single strand forms (lane 3,
sense; lane 4, antisense) and in a double strand form
(lane 9).
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shows enrichment of the myogenin promoter that is
comparable with the enrichment seen with an anti-
MyoD antibody in differentiating cells (Fig. 5B). Because
it was previously proposed that MSY-3 directly represses
the  cholinergic subunit gene (Sapru et al. 1996), we
extended the ChIP analysis to the AChR site. No signif-
icant enrichment of the AChR activity-dependent en-
hancer was observed, although the myogenin promoter
was again enriched (Supplemental Fig. 12). MSY-3 re-
quires an intact myogHCE sequence to bind at the myo-
genin promoter in cells, as shown by ChIP analysis of
C2C12 multiclone populations carrying the LacZ trans-
gene under the myogenin promoter wild type and mu-
tated (Fig. 5C). Furthermore, Figure 5D shows that when
Figure 4. Evidence MSY-3 inhibits myogenesis. (A) MSY-3 transfections of C2C12 myogenic cells. Expression during myogenic
differentiation of endogenous myogenin and MyoD measured by qRT–PCR of mock-transfected (pc) and a MSY-3-transfected (MSY-3)
C2C12 multiclonal populations, and two MSY-3-transfected clones (3 and 5). Immunoblot of extracts from MSY-3-overexpressing
C2C12 clones blotted with ZONAB (MSY-3 Ab) and -tubulin control. Two MSY-3 isoforms, short (S) and long (L). Myosin heavy chain
Ab marks differentiation (left) and Hoechst (right) stains of nuclei of the same C2C12 multiclone populations and clones 3, 5 at 72 h
in DM (full differentiation). Bar, 400 µm. (B) Effects of MSY-3 knockdown by siRNA. The immunoblot shows the two isoforms of
MSY-3 protein in extracts from C2C12 in GM, transfected with a pool of four interfering oligos (MiSmart) against MSY-3; or single
oligos (Mi1, Mi2, Mi3, Mi4), compared with control oligos (KiSmart). Levels of myogenin are reported and normalized relative to
-tubulin. Left graph shows the ratio of myogenin, MyoD,  AChR subunit, and MCK between the C2C12 in GM blocked with MSY-3
siRNA (MiSmart) or with control siRNAs (KiSmart). GAPDH was used to normalize. Anti myogenin Ab (left panel) and Hoechst (right)
staining of control siRNA (KiSmart) or MSY-3 siRNA (MiSmart). Bar, 200 µm. Graph quantifies myogenin positive C2C12 nuclei in
growth medium. (C) Mutational analysis of MSY-3 protein. C2C12-transformed cell lines overexpressing mutated forms of HA-tagged
MSY-3 protein were derived. In Supplemental Figure 10A expression of MSY-3-HA tagged in MSY-3 wild-type and mutant polyclone
populations is shown. Domain structure of MSY-3 protein and mutated forms derived N-PD (N-terminal proline-rich domain), CSD
(cold-shock domain), SHORT (splicing alternative domain), RP-CB (arginine- and proline-rich conserved domain), C-PD (C-terminal
praline-rich domain). The graph indicates the expression level of endogenous myogenin in the clones overexpressing the wild-type
MSY-3 protein, and the mutated forms in the CSD, SHORT, and the RP-CB domain. Myosin heavy chain Ab marks differentiation (top)
and Hoechst (bottom) stains nuclei of the same C2C12 multiclone populations at 72 h in DM (full differentiation). Bar, 400 µm.
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MSY-3 is knocked down in proliferating C2C12 cells,
ChIP enrichment of the myogenin promoter is greatly
reduced, compared with control cultures. The myogenin
locus is also detectably occupied by MyoD under these
conditions of MSY-3 knockdown, suggesting that MyoD
can bind the myogenin promoter prematurely under
myoblast growth conditions if, and only if, MSY-3 is re-
duced. This suggests that MSY-3 might act, at least in
part, by competing with MyoD for occupancy of myo-
genin promoter.
MSY-3 in adult muscle innervation
MSY-3 repression of myogenin in maturing and mature
muscle suggests that it may be directly involved in regu-
lating muscle responses to innervation and denervation.
Figure 6A shows that MSY-3 protein levels increases
during muscle maturation but start to decrease 6 h after
denervation. This profile is the opposite of those for
myogenin, MyoD, and AChR  subunit genes. We ex-
perimentally forced precocious MSY-3 expression in
neonatal muscle in vivo by electroporating quadriceps
and tibialis anterior muscles of 9-d-old mice with a
MSY-3 expression vector. Myogenin and  AChR RNA
expression, 5 d after electroporation, were reduced 60%
compared with levels in muscle receiving the control
construct (Fig. 6B). This is consistent with MSY-3 acting
as a negative regulator of myogenin in the animal. When
an MSY-3-expressing construct was electroporated into
denervated muscle, reduction was observed in tran-
scripts normally induced upon denervation, including
myogenin, MyoD, and  AChR. In contrast, no change
was detected in  AChR or muscle creatin kinase, genes
whose RNA is known to remain constant after denerva-
tion (Fig. 6C). We also attempted to reduce MSY-3 in
vivo by electroporating RNA-interfering oligos in the
tibialis anterior muscle of 2-mo-old mice; an increase of
∼50% in myogenin and AChR  transcript levels fol-
lowed, while there was no detectable elevation of the
innervation insensitive control gene, MCK (Fig. 6D, left).
Furthermore, the distribution of the AChR became dif-
fused over several millimeters from the synaptic junc-
tions in regions of the muscle where MSY-3 is knocked
out (Fig. 6D, right). These data are consistent with a role
for MSY-3 in repressing myogenin expression during
muscle innervation.
MSY-3 and Pbx occupy myogHCE region
during muscle maturation
An elegant study by Tapscott and colleagues (Berkes et
al. 2004) showed that the sequence domain located at
Figure 5. MSY-3 requires myoHCE to repress myo-
genin reporter and binds in vivo at myogenin pro-
moter. (A) Measurements of LacZ transgene reporter
by qRT–PCR in C2C12 clones. LacZ is under the
control of the wild-type myogenin promoter
(pcMwt, MsyMwt) or mutated variants (pcmutL,
MsymutL pcmutT, MsymutT) in mock-transfected
(pc) and MSY-3-overexpressing (Msy) C2C12 cells.
Expression level reported as log ratio of LacZ mu-
tated/wild type, normalized by endogenous myo-
genin. Neomycin and puromycin expression mark-
ers used to check that transgene incorporation levels
were similar. (B) ChIP analysis for MSY-3 and
MyoD. Control IgG, MSY-3, and MyoD antibodies
were used individually to enrich fixed chromatin
from undifferentiated (GM) or differentiated (DM)
C2C12 cells. qRT–PCR is used to quantify se-
quences from the myogenin promoter and the nega-
tive control IgH enhancer. (C) Chromatin from mul-
ticlone populations carrying LacZ under MYO and
MYOL promoter control growth in GM. qRT-PCR
used to quantify for the ectopic myogenin promoter-
LacZ fragment (left) and the endogenous myogenin
promoter (right). (D) Chromatin from undifferenti-
ated C2C12 transfected with the pool of four inter-
fering oligos (Mi) that knocks down MSY-3 or con-
trol oligos (Ki). Figure displays results representative
from three independent ChIP experiments.
Berghella et al.
2132 GENES & DEVELOPMENT
−98 of the mouse myogenin promoter is required by
MyoD for a stable binding to the myogenin promoter
region. They showed that this binding by MyoD is im-
portant for a chromatin opening function that normally
precedes myogenin activation, and that it requires an
interaction with the homeodomain protein Pbx, which
binds at a site adjacent to MyoD. That led us to hypoth-
esize that Pbx might also interact with MSY-3 in the
innervation-stimulated repression function. The expres-
sion level of two of the three isoforms of Pbx (Pbx1 and
Pbx3) suggests a possible role in adult muscle innerva-
tion (Fig. 7A). Both isoforms reach their peaks of expres-
sion around day 20 of postnatal life when normal inner-
vation is prominent and when myogenin is aggressively
down-regulated (Fig. 6A). To determine if Pbx is bound at
the myogenin locus in muscle, and to compare its occu-
pancy with that of MSY-3 and MyoD during maturation,
we performed ChIP experiments. Pbx ChIP displayed
greater enrichment from muscle of 2-wk-old and 2-mo-
old mice, compared with muscle from younger mice (2 d
and 1 wk), as did MSY-3 (Fig. 7B). To determine if Pbx
protein and MSY-3 can bind to the same fragment of the
myogenin promoter simultaneously, we performed a se-
quential RE-Chip assay; by immunoprecipitating with
the Pbx antisera the chromatin first immunoprecipitated
with the anti-MSY-3 antibody. We observed an enrich-
ment of the immunoprecipited chromatin when the
muscle had been innervated recently (2 wk), suggesting
that the association between Pbx and MSY-3 at the myo-
genin locus is simultaneous in vivo in recently inner-
vated muscle (Fig. 7C). MSY-3 requires an intact
myogHCE sequence to bind at the myogenin promoter in
vivo, as shown by ChIP analysis of muscle from LacZ
transgenic mouse, lines MYOwt and MYOmutL (Supple-
mental Fig. 13).
To test the possibility that the myogHCE-like con-
served element located 35 kb upstream of MyoD
(chr7:42,517,839–42,517,855, UCSC mm7) might also
bind MSY-3 in vivo, ChIP assays were performed.
MSY-3 enrichment was detected at the upstream MyoD
domain, similar to results for the −1.1-kb myogenin
region, although the two loci differed in extent of
occupancy by MyoD (Fig. 7B, bottom), which might be
related to the presence of a canonical E-box in the HCE-
related MyoD sequence versus a noncanonical one in
myogenin.
Figure 6. MSY-3 in adult muscle inner-
vation. (A) Expression of MSY-3 protein
and myogenin, MyoD and AChR  sub-
unit RNA in muscle at different times of
maturation (immunoblot and graph, left)
and after denervation by sciatic nerve tran-
section (immunoblot and graph, right). (B)
Expression of myogenin and AChR  sub-
unit genes after electroporation in tibialis
anterior and quadriceps muscle of young
mice (14 d postnatal) of the control
(pcDNA3) and MSY-3 (pcDNA3-MSY-3)
constructs evaluated by qRT–PCR. (C) Ex-
pression of myogenin, MyoD, AChR 
subunit, MCK, and AChR  in adult (2 mo)
tibialis anterior muscle (control) electro-
porated with pcDNA3 (pc); electroporated
with MSY-3 (MSY-3); electroporated with
the same constructs and later denervated
by sciatic nerve transection (pcD and
MSY-3D). Expression was evaluated by
qRT–PCR and immunoblot (MSY-3). (D,
left) Expression of myogenin, AChR  sub-
unit, and MCK in tibialis anterior muscle
of adult mice (2 mo) elecroporated with a
pool of four interfering oligos (Mi), which
blocks MSY-3 or with control oligos (Ki),
coinjected with a nuclear GFP-expressing
plasmid (Mi* and Ki*) in order to dissect
only the injected area and evaluated by
qRT–PCR. The immunoblot measures
MSY-3 expression. (Right) AChRs density
in extrasynaptic regions (3 mm from syn-
aptic junctions) visualized by autoradiog-
raphy of longitudinal sections from Ki* or
Mi* electroporated tibialis anterior muscle
of adult mice (2 mo old) and incubated
with 125 I--bungarotoxin. Bar, 200 µm.
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Discussion
The central findings of this study spring from the obser-
vation that the myogHCE conserved cis element is criti-
cal for transcriptional repression of myogenin in postna-
tal muscle maturation. We then identified MSY-3 as a
trans-acting factor that binds to the myogHCE in vivo
and in vitro and can mediate repression. Regulation of
myogenin expression has been of longstanding interest
because myogenin plays a critical and unique role in the
muscle regulatory network as a direct positive-acting
transcription factor for hundreds of skeletal muscle dif-
ferentiation genes, including autoregulation and positive
cross-talk with other transcription factors of the core
myogenin gene regulatory network. But myogenin ex-
pression does not continue at high levels in normal adult
muscle, and MRF4 ultimately becomes the major MRF
family member. The down-regulation of myogenin in
mature muscle also has a spatial dimension related to
innervation. Thus, AChRs, MusK, rapsyn, and other pro-
teins necessary for AChR subunit clustering at neuro-
muscular synapses are especially myogenin sensitive,
and their expression is broadly repressed in most extra-
junctional myonuclei in response to muscle innervation.
Levels of myogenin and MyoD expression appear to be
crucial in this process (Blais et al. 2005; Macpherson et
al. 2006).
Our findings suggest that the myogHCE/MSY-3 regu-
latory node plays a key role in the spatiotemporal repres-
sion of myogenin in mature, innervated muscle. We do
not yet know exactly how MSY-3, which apparently oc-
cupies the myogHCE motif in collaboration with Pbx,
mediates repression. One possibility is suggested by re-
cent studies that point to HDAC activity at the myo-
genin locus (Mejat et al. 2005; Tang and Goldman 2006).
HDAC recruitment has been associated with MEF2 and
Six factors in those studies, and both have conserved
sequence motifs located between the myogHCE and the
myogenin promoter. The fact that we observed small,
but nevertheless statistically significant, repression in
our assays of myogHCE mutant transgene activity is
consistent with the idea that myogenin repression has
multiple contributing elements, and that MEF2/HDAC
and Six/Dach/HDAC are likely to be responsible for this
additional repression activity. However the effects that
remained after the HCE was eliminated were quantita-
tively quite minor in our study, and this is consistent
with the observation that HDAC inhibition by tricho-
statin in mature innervated muscle failed to relieve myo-
genin repression (Tang and Goldman 2006). It is attrac-
tive to think that the three cis–trans systems together
ensure repression, and there might be significant inter-
play between MSY-3 and HDAC systems.
In the C2C12 cell culture model of muscle differentia-
tion, which precedes the maturation events discussed
above, the myogHCE cis element can act positively
rather than negatively, and it does so by binding MyoD
Figure 7. MSY-3 and Pbx binding to the
myogHCE region in vivo. (A) Expression of
three isoforms of Pbx in muscle at differ-
ent times of maturation are evaluated by
qRT–PCR. (B) ChIP analysis with control
IgG, MSY-3, MyoD, and Pbx antibodies on
chromatin from tibialis anterior muscle of
young (2dd, 1w, and 2ww); adult (2MM); or
denervated (2MMD) mice. Following im-
munoprecipitation, DNA enrichment was
measured by qRT–PCR for myogenin pro-
moter (top left), control IgH enhancer (top
right), or −35-kb MyoD enhancer (bottom).
(C) A sequential ChIP (RE-ChIP) experi-
ment. Chromatin immunoprecipitated
with MSY-3 was reincubated with anti
Pbx (Pbx/MSY-3) or vice-versa (MSY-3
then Pbx). Results shown are representa-
tive of three independent experiments.
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and Pbx (Berkes et al. 2004). MSY-3 is expressed in C2
cells, and this raised the question of whether it has the
capacity to repress premature differentiation in myo-
blasts or it could alter the onset of differentiation. In
C2C12 cells, where the chromatin opening function was
first discovered, we found we could alter myogenin ex-
pression (and its positive regulatory effects on differen-
tiation), by elevating or reducing MSY-3 relative to its
normal levels. The simplest interpretation of these re-
sults is that, in the presence of both MyoD and MSY-3,
the HCE can act in either a positive or negative manner,
and the choice depends on the relative levels and activi-
ties of the positive (MyoD) or negative (MSY-3) factors,
both of which seem to collaborate with PBX. This ap-
pears to be one instance of a more general regulatory
strategy that features dual function cis-regulatory ele-
ments. Thus, they normally switch their regulatory sign
from positive, which dominates during muscle differen-
tiation (MEF2, Six-1, MyoD/PBX, in association with
their coactivators), to negative, which dominates during
muscle maturation and innervation (MEF2 and Six/Dach
in association with HDACs and MSY-3/PBX).
When we studied the effects of the myogHCE on ex-
pression in lentiviral transgenic mice, we did not see an
obvious phenotype corresponding to the activating one
already described in C2C12 cells (Berkes et al. 2004). We
saw apparently normal LacZ reporter expression from
the mutated contructs at sites in the embryos where new
myogenic differentiation is occurring, such as young
caudal somites and limb buds. These are domains where
one might have expected to see effects from a failure of
chromatin opening as a failure to turn on at the same
time as wild type, or to activate to the same extent.
Failure to see a clear effect of this kind at first seemed
surprising, but the LacZ staining assay we used may not
be quantitative enough to detect lowered myogenin ac-
tivation on a cell-by-cell basis, nor sensitive enough to
pick up a more gradual up-regulation. In addition, the
lentiviral vector could be providing its own chromatin
open domain information that accomplishes for the con-
struct what the myogHCE normally does in the native
myogenin locus.
During postnatal development, both lentiviral and
conventional transgenic assay systems revealed a robust
myogHCE effect on postnatal myogenin expression. The
fact that myogenin is strongly repressed postnatally is
generally compatible with the fact that a conditional
knockout, which takes its full effect in this time period,
is not lethal and mainly alters adult animal size (Knapp
et al. 2006). That study does, however, raise the question
of whether there is normally a time during or after
muscle maturation when myogenin ceases to be impor-
tant to specific endogenous target genes expressed at
junctional myonuclei, and what regulators take over that
job when myogenin is knocked out.
Previous studies showed there are some additional cis-
acting myogenin regulatory regions that are responsive
to electrical activity in postnatal life, positioned up-
stream (i.e., between −1102 and −1565) relative to the
region in our constructs (Gibney and Buonanno 1995).
To our knowledge, the cis elements in that more distal
region have not been more finely localized. We did not
find a second sequence motif similar to myogHCE over
entire myogenin locus, but it is possible and even likely
that additional cis-acting modules contribute to nerve-
mediated myogenin regulation. The possibility that
MSY-3 might directly repress additional genes that are
differentially expressed in extrajunctional myonuclei
synaptic ones is an idea with some appeal, since it would
be a way to provide regulatory robustness and/or fine-
tuning. A specific role for MSY-3 in regulating the AChR
 subunit gene would fit this model and is supported by
a prior observation of in vitro binding by MSY-3 (Sapru et
al. 1996). However, that study did not demonstrate in
vivo occupancy of the AChR enhancer, so we performed
ChIP experiments. No interaction was detected under
conditions that gave positive enrichment for MSY-3 at
the myogenin HCE. We do not know if this is a technical
experimental difference—perhaps revolving around the
sensitivity of ChIP enrichment—or a biological differ-
ence between occupancy at myogenin and the possible
occupancy at AChR . In any case, the fact that AChR
expression is disregulated by ectopic myogenin in our
experiments argues that the MSY-3 normally present in
the system is not sufficient to keep AChRs fully re-
pressed on its own.
MSY-3 appears to be a versatile factor, and it is likely
to have regulatory targets other than myogenin in our
system. They need not all be repressive. For example,
MSY-3 has been reported as a positive acting regulator of
genes associated with cell cycle progression (Sourisseau
et al. 2006). In particular, our observation in myogenesis
that MSY-3 overexpression induces some muscle appar-
ent hypertrophy is consistent with the idea that it has
multiple effects, some of which might be independent of
DNA binding, as suggested by the CSD mutant pheno-
type.
Although it was not a focus of this study, we found
some initial evidence that MyoD might also be directly
affected by MSY-3. A match for the myogHCE PSFM was
discovered within a larger, unstudied conserved feature
located at ∼35 kb upstream of MyoD transcription ini-
tiation in mouse, and 10 kb upstream of the major “core”
MyoD enhancer (Goldhamer et al. 1995). By ChIP crite-
ria, MSY-3 binds to the −35-kb region in vivo. The pos-
sibility that both MyoD and myogenin are affected by
the same repressor complex during muscle innervation,
recognizable by a similar cis motif, has appealing sim-
plicity and would help to explain the strong phenotypic
effects of MSY-3 ectopic expression and knockdown.
Multiple lines of evidence presented here support the
view that myogHCE is a critical cis element for repres-
sion of myogenin. The myogHCE is composed of partly
overlapping binding sites for MyoD, MSY-3, and PBX,
and the partial overlap of binding sites provides a plau-
sible explanation for strong conservation over great
distances that separate mammals and fish. It also could
provide a way to make the regulatory states mutually
exclusive, and therefore switch-like. However, the
preferential conservation does not correspond, in this
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case, to biochemical optimality of the individual binding
motifs for the individual factors. Quite the opposite is
true, since none of the sites in myogHCE would even be
identified by sequence inspection as motifs for MyoD,
MSY-3, or Pbx. Multiple weak individual binding motifs
could, however, offer special advantages for regulating
cell state transitions, which we understand myogenin
does. Thus, individually weak binding sites, stably occu-
pied only when all members of a multifactor complex are
present at high levels and in the right modification
states, should prevent erroneous changes of state; yet
they would also be sensitive, on a rapid time scale, to big
changes in any one component, which would readily de-
stabilize the entire complex. For myogenin, the paths
would be from repressed in myoblasts to active in early
differentiation; from active in early differentiation to a
repressed state in innervated mature myofibers; and still
later, from repressed in healthy innervated myofibers to
reactivated upon denervation or, perhaps, to degenera-
tion, which has not yet been explored. Although evolu-
tion of the myogHCE and its surrounding locus cannot
be tested directly, the impact of “optimizing” individual
motifs, and their pairwise combinations, in the
myogHCE should be experimentally accessible using as-
say systems developed here for repression and previously
by Berkes et al. (2004) for activation.
The three cis-regulatory themes proposed for myo-
genin—(1) highly conserved biochemical suboptimality
in the HCE, for sensitivity and specificity; (2) conserved
binding site overlap for exclusivity of action between
MyoD and MSY-3, in the HCE; and (3) individual cis
elements able to bind complexes of opposing activites,
according to cell context (Six, MEF2, as well as HCE)—
can now be searched for in other systems to see if they
are general and if they are especially used for regulators
of cell state.
Materials and methods
Comparative genomics
Procedures are described in the Supplemental Material.
Cell, transfections, and tissue cultures
293T, C2C12, and C3H10T1/2 cells were from American Type
Culture Collection. C2C12 cells were cultured in DMEM
supplemented with 20% FBS (GM) and induced to differentiate
with DMEM supplemented with 2% horse serum (DM, differ-
entiation medium). 293T and 10T1/2 were cultured in 10% FBS.
Transfections and stable clones were generated as described in
the Supplemetal Material. Muscle fiber cultures were performed
as described in Cornelison and Wold (1997).
Plasmids and lentiviral constructs
Constructs and the cloning details are described in the Supple-
mental Material. For the lentiviral transgenesis we gener-
ated the wild-type myogenin promoter lentiviral vector
pFMYOwtLacZ and the mutated versions pFMYOmutLLacZ
and pFMYOmutTLacZ as described in Supplemental Figure 2.
Lentiviral and conventional transgenesis
Injection of lentiviruses into mouse embryos was performed
according to Lois et al. (2002). Details of conventional transgen-
esis and lentiviral tritation and transgenics analysis are de-
scribed in the Supplemental Material and in Supplemental
Table S2.
Detection of acetylcholine receptors
The density of AChRs in muscle was determined as described
by Gundersen et al. (1995), with the exception that longitudinal
sections of tibialis anterior muscle were incubated with 125
I--bungarotoxin and then processed as described.
Tandem affinity purification MudPIT
MudPIT mass spec analysis of proteins retrieved from affinity
enrichment by binding to myogHCE DNA was performed es-
sentially as described in Graumann et al. (2004). Samples were
proteolytically digested and analyzed by multidimensional
chromatography in-line with a Deca XP ion trap mass spectrom-
eter (ThermoElectron). Samples were released stepwise from
the strong cation exchanger phase of the triphasic capillary col-
umns as reported previously (Graumann et al. 2004).
In vivo electroporation
Tibialis anterior and quadriceps muscles were electroporated as
previously described with minor modifications (Protocol 2,
Martinenghi et al. 2002). Briefly, mice were anesthetized by
avertin injection, and expression vectors were injected with a
0.5-m insulin syringe through a 27-gauge needle into quadriceps
and tibialis anterior muscles of 9-d CD1 male mice (20 µg of
each plasmid in a costant volume of 20 µL of PBS) and into
tibialis anterior muscles of 2-mo-old CD1 female mice (50 µg of
each plasmid in 50 µL of PBS). A pair of stainless steel plates was
then applied over the muscle to encompass the injection area.
Current was delivered 5 to 10 min after DNA injection as a
constant current, square-wave pulse with a digital Stimulator
(Panlab 3100, Biological Instruments) and checked by a digital
oscilloscope (Tektronix TDS210). The characteristics of the
electric field applied were 200 V/cm, 20 msec amplitude, 1 Hz,
eight consecutive. In denervation experiments the tibialis ante-
rior muscles were denervated by sciatic nerve transection 8 d
later than electroporation and tissue was processed for RNA
extraction 24 h later than denervation. In each electroporation
experiment, 5 µg of a lentiviral vector expressing nuclear GFP is
coinjected and, when indicated by *, the GFP postitive area was
dissected to restrict the injection area for successive analysis.
RNAi
The duplex siRNA sequences used in RNAi are Mi1, CGACG
UCCCUACAACUAUAUU; Mi2, CGUCAGAAAUGGAUAU
GGAUU; Mi3, AAACAACCCACGCAAGUAUUU; Mi4, CA
ACGCUGUUUCACAAGAUUU.
Methods are described in the Supplemental Material.
For quantitative real time PCR, preparation of recombinant
and nuclear protein, EMSA, immunoblot analysis, and ChiP
assay, the methods are described in the Supplemental Material.
Acknowledgments
We thank Shirley Pease (Laboratory Animal Resource, Caltech)
for transgenic production, Marcello Coletta for technical help in
Berghella et al.
2136 GENES & DEVELOPMENT
denervation experiments, Leslie Dunipace for technical assis-
tance, Dr. Carlos Lois for parental lentiviral vectors, Dr. Cathy
Yuh for help in Affinity Chromatography procedures, Dr. Dario
Coletti for help in mice leg electroporation, Hiroke Shizuya for
mouse BAC library, Diane Trout for MUSSAGL and genome
comparison figures; and Dr. Johannes Graumann for MudPIT
analysis performed in the Caltech Beckman Institute PEL cen-
ter. We are grateful to Drs. C. Berkes and Stephen Tapscott for
valuable discussion and exchange of reagents results prior to
publication. We also acknowledge Dr. Pier Lorenzo Puri for
helpful discussion. This work was supported by NIH, DOE, and
NASA grants to B.J.W. and Fondation Leducq, BMW, Duchenne
Parent Project, FIRB, and EcMyoAmp grants to G.C.
References
Berberich, C., Durr, I., Koenen, M., and Witzemann, V. 1993.
Two adjacent E box elements and a M-CAT box are involved
in the muscle-specific regulation of the rat acetylcholine re-
ceptor beta subunit gene. Eur. J. Biochem. 216: 395–404.
Berkes, C.A., Bergstrom, D.A., Penn, B.H., Seaver, K.J., Knoep-
fler, P.S., and Tapscott, S.J. 2004. Pbx marks genes for acti-
vation by MyoD indicating a role for a homeodomain protein
in establishing myogenic potential. Mol. Cell 14: 465–477.
Blagden, C.S., Fromm, L., and Burden, S.J. 2004. Accelerated
response of the myogenin gene to denervation in mutant
mice lacking phosphorylation of myogenin at threonine 87.
Mol. Cell. Biol. 24: 1983–1989.
Blais, A., Tsikitis, M., Acosta-Alvear, D., Sharan, R., Kluger, Y.,
and Dynlacht, B.D. 2005. An initial blueprint for myogenic
differentiation. Genes & Dev. 19: 553–569.
Buonanno, A., Apone, L., Morasso, M.I., Beers, R., Brenner,
H.R., and Eftimie, R. 1992. The MyoD family of myogenic
factors is regulated by electrical activity: Isolation and char-
acterization of a mouse Myf-5 cDNA. Nucleic Acids Res. 20:
539–544.
Buonanno, A., Edmondson, D.G., and Hayes, W.P. 1993. Up-
stream sequences of the myogenin gene convey responsive-
ness to skeletal muscle denervation in transgenic mice.
Nucleic Acids Res. 21: 5684–5693.
Cheng, T.C., Wallace, M.C., Merlie, J.P., and Olson, E.N. 1993.
Separable regulatory elements governing myogenin tran-
scription in mouse embryogenesis. Science 261: 215–218.
Cohen, T.J., Waddell, D.S., Barrientos, T., Lu, Z., Feng, G., Cox,
G.A., Bodine, S.C., and Yao, T. 2007. The histone deacety-
lase HDAC4 connects neural activity to muscle transcrip-
tional reprogramming. J. Biol. Chem. 282: 33752–33759.
Coles, L.S., Diamone, P., Occhiodoro, F., Vadas, M.A., and
Shannon, M.F. 2000. An ordered array of cold shock domain
repressor elements across tumor necrosis factor responsive
elements of the granulocyte–macrophage colony-stimulat-
ing factor promoter. J. Biol. Chem. 275: 14482–14493.
Coles, L.S., Lambrusco, L., Burrows, J., Hunter, J., Diamond, P.,
Bert, A.G., Vadas, M.A., and Goodall, G.J. 2005. Phosphory-
lation of cold shock domain/Y box proteins by ERK2 and
GSK3 and repression of the human VEGF promoter. FEBS
Lett. 579: 5372–5378.
Cornelison, D.D. and Wold, B.J. 1997. Single-cell analysis of
regulatory gene expression in quiescent and activated mouse
skeletal muscle satellite cells. Dev. Biol. 191: 270–283.
Edmondson, D.G., Cheng, T.C., Cserjesi, P., Chakraborty, T.,
and Olson, E.N. 1992. Analysis of the myogenin promoter
reveals an indirect pathway for positive autoregulation me-
diated by the muscle-specific enhancer factor MEF-2. Mol.
Cell. Biol. 12: 3665–3677.
Eftimie, R., Brenner, H.R., and Buonanno, A. 1991. Myogenin
and MyoD join a family of skeletal muscle genes regulated
by electrical activity. Proc. Natl. Acad. Sci. 88: 1349–1353.
Fontaine, B., Sasson, D., Buckingham, M., and Changeux, J.P.
1988. Detection of nicotinic acetylcholine receptor a-sub-
unit mRNA by in situ hybridization at neuromuscular junc-
tions of 15-day old chick striate muscles. EMBO J. 7: 603–
609.
Gibney, G. and Buonanno, A. 1995. Analysis of neural-respon-
sive myogenin upstream sequences by myoblast implanta-
tion. Dev. Biol. 172: 614–624.
Goldhamer, D.J., Brunk, B.P., Faerman, A., King, A., Shani, M.,
and Emerson Jr., C.P. 1995. Embryonic activation of the
myoD gene is regulated by a highly conserved distal control
element. Development 121: 637–649.
Goldman, D. and Staple, J. 1989. Spatial and temporal expres-
sion of acetylcholine receptor RNAs in innervated and de-
nervate rat soleus muscle. Neuron 3: 219–228.
Graumann, P.L. and Marahiel, M.A. 1998. Superfamily of pro-
teins that contain the coldshock domain. Trends Biochem.
Sci. 23: 286–290.
Graumann, J., Dunipace, L.A., Seol, J.H., McDonald, W.H.,
Yates III, J.R., Wold, B.J., and Deshaies, R.J. 2004. Applica-
bility of tandem affinity purification MudPIT to pathway
proteomics in yeast. Mol. Cell. Proteomics 3: 226–237.
Grounds, M.D., Garrett, K.L., Lai, M.C., Wright, W.E., and Beil-
harz, M.W. 1992. Identification of skeletal muscle precursor
cells in vivo by use of MyoD1 and myogenin probes. Cell
Tissue Res. 267: 99–104.
Gundersen, K., Rabben, I., Klocke, B.J., and Merlie, J.P. 1995.
Overexpression of Myogenin in muscles of transgenic mice:
Interaction with Id-1, negative crossregulation of myogenic
factors, and induction of extrasynaptic acetylcoline receptor
expression. Mol. Cell. Biol. 15: 7127–7134.
Hannon, K., Smith II, C.K., Bales, K.R., and Santerre, R.F. 1992.
Temporal and quantitative analysis of myogenic regulatory
and growth factor gene expression in the developing mouse
embryo. Dev. Biol. 151: 137–144.
Hasty, P., Bradley, A., Morris, J.H., Edmondson, D.G., Venuti,
J.M., Olson, E.N., and Klein, W.H. 1993. Muscle deficiency
and neonatal death in mice with a targeted mutation in the
myogenin gene. Nature 364: 501–506.
Knapp, J.R., Davie, J.K., Myer, A., Meadows, E., Olson, E.N., and
Klein, W.H. 2006. Loss of myogenin in postnatal life leads to
normal skeletal muscle but reduced body size. Development
133: 601–610.
Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., and Kuwano,
M. 2003. The pleiotropic functions of the Y-box-binding pro-
tein, YB-1. Bioessays 25: 691–698.
Kostrominova, T.Y., Macpherson, P.C.D., Carlson, B.M., and
Goldman, D. 2000. Regulation of myogenin protein expres-
sion in denervated muscles from young and old rats. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 279: R179–R188.
Lassar, A.B., Buskin, J.N., Lockshon, D., Davis, R.L., Apone, S.,
Hauschka, S.D., and Weintraub, H. 1989. MyoD is a se-
quence-specific DNA binding protein requiring a region of
myc homology to bind to the muscle creatine kinase en-
hancer. Cell 58: 823–831.
Lois, C., Hong, E.J., Pease, S., Brown, E.J., and Baltimore, D.
2002. Germline transmission and tissue-specific expression
of transgenes delivered by lentiviral vectors. Science 295:
868–872.
Macpherson, P., Kostrominova, T., Tang, H., and Goldman, D.
2002. Protein kinase C and calcium/calmodulin-activated
protein kinase II (CaMK II) suppress nicotinic acetylcholine
receptor gene expression in mammalian muscle. A specific
Myogenin repression in muscle maturation
GENES & DEVELOPMENT 2137
role for CaMK II in activity-dependent gene expression. J.
Biol. Chem. 277: 15638–15646.
Macpherson, P.C., Cieslak, D., and Goldman, D. 2006. Myo-
genin-dependent nAChR clustering in aneural myotubes.
Mol. Cell. Neurosci. 31: 649–660.
Martinenghi, S., Cusella De Angelis, G., Biressi, S., Amadio, S.,
Bifari, F., Roncarolo, M.G., Bordignon, C., and Falqui, L.
2002. Human insulin production and amelioration of diabe-
tes in mice by electrotransfer-enhanced plasmid DNA gene
transfer to the skeletal muscle. Gene Ther. 21: 1429–1437.
Mastrangelo, M. and Kleene, K.C. 2000. Developmental expres-
sion of Y-box protein 1 mRNA and alternatively spliced Y-
box protein 3 mRNAs is spermatogenic cells in mice. Mol.
Hum. Reprod. 6: 779–788.
Matsumoto, K. and Wolffe, A.P. 1998. Gene regulation by Y-box
proteins: Coupling control of transcription and translation.
Trends Cell Biol. 8: 318–323.
Mejat, A., Ramond, F., Bassel-Duby, R., Khochbin, S., Olson,
E.N., and Schaeffer, L. 2005. Histone deacetylase 9 couples
neuronal activity to muscle chromatin acetylation and gene
expression. Nat. Neurosci. 8: 313–321.
Mendelzon, D., Changeux, J.P., and Nghiem, H.O. 1994. Phos-
phorylation of myogenin in chick myotubes: Regulation by
electrical activity and by protein kinase C. Implications for
acetylcholine receptor gene expression. Biochemistry 33:
2568–2575.
Mortazavi, A., Thompson, E.C., Garcia, S.T., Myers, R.M., and
Wold, J.B. 2006. Comparative genomics modeling of the
NRSF/REST repressor network: From single conserved sites
to genome-wide repertoire. Genome Res. 16: 1208–1221.
Musarò, A., Cusella De Angelis, M.G., Germani, A., Ciccarelli,
C., Molinaro, M., and Zani, B.M. 1995. Enhanced expression
of myogenic regulatory genes in aging skeletal muscle. Exp.
Cell Res. 221: 241–248.
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S.,
Nonaka, I., and Nabeshima, Y. 1993. Myogenin gene disrup-
tion results in perinatal lethality because of severe muscle
defect. Nature 364: 532–535.
Penes, M.C., Li, X., and Nagy, J.I. 2005. Expression of zonula
occludens-1 (ZO-1) and the transcription factor ZO-1-asso-
ciated nucleic acid-binding protein (ZONA-B)-MSY3 in glial
cells and colocalization at oligodendrocyte and astrocyte gap
junctions in mouse brain. Eur. J. Neurosci. 22: 404–418.
Piette, J., Bessereau, J.L., Huchet, M., and Changeux, J.P. 1990.
Two adjacent MyoD1-binding sites regulate expression of
the acetylcholine receptor -subunit gene. Nature 345: 353–
355.
Prody, C.A. and Merlie, J.P. 1991. A developmental and tissue-
specific enhancer in the mouse skeletal muscle acetylcho-
line receptor -subunit gene regulated by myogenic factors.
J. Biol. Chem. 266: 22588–22596.
Sanes, J.R. and Lichtman, J.W. 2001. Induction, assembly, matu-
ration and maintenance of a postsynaptic apparatus. Nat.
Rev. Neurosci. 2: 791–805.
Sapru, M.K., Gao, J.P., Walke, W., Burmeister, M., and Gold-
man, D. 1996. Cloning and characterization of a novel tran-
scriptional repressor of the nicotinic acetylcholine receptor
-subunit gene. J. Biol. Chem. 271: 7203–7211.
Sassoon, D., Lyons, G., Wright, W.E., Lin, V., Lassar, A., Wein-
traub, H., and Buckingham, M. 1989. Expression of two myo-
genic regulatory factors myogenin and MyoD1 during mouse
embryogenesis. Nature 341: 303–307.
Shannon, M.F., Coles, L.S., Vadas, M.A., and Cockeril, P.N.
1997. Signals for activation of the GM-CSF promoter and
enhancer in T cells. Crit. Rev. Immunol. 17: 301–323.
Sourisseau, T., Georgiadis, A., Tsapara, A., Ali, R.R., Pestell, R.,
Matter, K., and Balda, M.S. 2006. Regulation of PCNA and
cyclin D1 expression and epithelial morphogenesis by the
ZO-1-regulated transcription factor ZONAB/DbpA. Mol.
Cell. Biol. 26: 2387–2398.
Spitz, F., Demignon, J., Porteu, A., Kahn, A., Concordet, J.P.,
Daegelen, D., and Maire, P. 1998. Expression of myogenin
during embryogenesis is controlled by Six/sine oculis ho-
meoproteins through a conserved MEF3 binding site. Proc.
Natl. Acad. Sci. 95: 14220–14225.
Tang, H. and Goldman, D. 2006. Activity-dependent gene regu-
lation in skeletal muscle is mediated by a histone deacety-
lase (HDAC)–Dach-2–myogenin signal transduction cas-
cade. Proc. Natl. Acad. Sci. 103: 16977–16982.
Venuti, J.M., Morris, J.H., Vivian, J.L., Olson, E.N., and Klein,
W.H. 1995. Myogenin is required for late but not early as-
pects of myogenesis during mouse development. J. Cell Biol.
128: 563–576.
Walke, W., Xiao, G., and Goldman, D. 1996. A dual function
activity-dependent, muscle-specific enhancer from rat nico-
tinic acetylcholine receptor -subunit gene. J. Neurobiol. 31:
359–369.
Wright, W.E., Sasson, D.A., and Lin, V.K. 1989. Myogenin, a
factor regulating myogenesis, has a domain homologous to
MyoD. Cell 56: 607–617.
Yee, S.P. and Rigby, P.W. 1993. The regulation of myogenin
gene expression during the embryonic development of the
mouse. Genes & Dev. 7: 1277–1289.
Berghella et al.
2138 GENES & DEVELOPMENT
